1. Home
  2. Mandates
  3. Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

Mandate Vinge advised Ysios Capital, OrbiMed and others in connection with their investment in Galecto Biotech

October 29, 2018

Galecto Biotech AB, the developer of galectin modulators for the treatment of severe diseases, including fibrosis and cancer, has closed a €79 million financing co-led by Ysios Capital and OrbiMed.

New investors Ysios Capital, OrbiMed, HBM Healthcare Investments, OrbiMed Israel, Bristol Myers-Squibb, Maverick Ventures and Seventure Partners joined existing investors Novo Seeds, M Ventures, and Sunstone Capital in the financing round.
 
Vinge advised the new investors. The Vinge team included Jesper Ottergren, Erik Sjöman and Charlotte Akej.
 

Compliance policies and dawn raid manuals should be revised in light of amendments to the Swedish Competition Act

As previously described, the Swedish Competition Act (2008:579) will be amended in several important respects on 4 February 2021. We recommend that you revise your current compliance policies and manuals for dawn raids to ensure adherence with the new rules.
November 25, 2020

Jerker Kjellander is a new partner in Skåne

 Dispute resolution expert Jerker Kjellander has been elected as a partner in Vinge’s Skåne office.
November 20, 2020

Amendments to the Swedish Competition Act provide extended powers for the Swedish Competition Authority

Early in 2021, the Swedish Competition Act (2008: 579) will be amended in several important respects. The background to the amendments is Directive (EU) 2019/1 of the European Parliament and of the Council, which aims to harmonize the investigative and sanctioning powers of the European competition authorities in their enforcement of the EU competition rules. Undertakings active in Sweden will be affected by the amendments in several ways.
October 12, 2020